Clearmind Medicine Inc. announced progress in its multinational Phase I/IIa clinical trial evaluating CMND-100, a proprietary non-hallucinogenic MEAI-based oral compound for the treatment of Alcohol Use Disorder. In 2025, the company completed site activations at institutions including Yale School of Medicine, Johns Hopkins University School of Medicine, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center. The first-in-human dosing was initiated, and treatment and enrollment for the first cohort were completed, with positive top-line safety and tolerability results reported and no serious adverse events observed. The Data and Safety Monitoring Board unanimously approved the continuation of the trial after an interim review. Enrollment and dosing for the second cohort have also been completed, with further data readouts expected in the future.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-125574), on December 29, 2025, and is solely responsible for the information contained therein.